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Osteoanabolic therapy is an attractive therapeutic option for men with osteoporosis because it directly stimulates bone formation,
an action not shared by any antiresorptive drug. Teriparatide (recombinant human PTH(1-34)) and PTH(1-84) are available in
many countries but PTH(1-84)isnot available in theUnited States. Only teriparatideis approved forthetreatment of osteoporosis
in men. It is also indicated in glucocorticoid-induced osteoporosis. Teriparatide is associated with major gains in bone density at
the lumbar spine and, to a lesser extent, in the hip regions. Vertebral and nonvertebral fractures are reduced in postmenopausal
women treated with teriparatide. Fracture reduction data in men are less secure because the number of study subjects is small
and the studies have not been powered to document this endpoint. Nevertheless, observational data in men suggest a reduction in
vertebral fractures with teriparatide. Attempts to show further beneﬁcial eﬀects of teriparatide in combination with antiresorptive
agents have not been demonstrated yet to be superior to monotherapy with teriparatide alone. The duration of therapy with
teriparatide is limited to 2 years. Thereafter, it is necessary to treat with an antiresorptive drug to maintain, and perhaps increase,
densitometric gains. Teriparatide is well tolerated with a good safety proﬁle.
1.Introduction
PTH(1-84) and its foreshortened variant, teriparatide
(PTH(1-34)), represent the only available osteoanabolic
therapies for osteoporosis. In contrast to antiresorptive
therapies, which are the mainstay of osteoporotic treatment,
these agents directly stimulate bone formation, and as
a result, improve not only bone mass but also skeletal
microstructure, including trabecular connectivity and corti-
cal thickness.
Although postmenopausal women are the dominant
cohort at risk for osteoporosis, men are not spared. Current
ﬁgures show that men represent approximately 25% of all
osteoporoticindividuals[1].Morbidityandmortalityﬁgures
after a hip fracture in men are disproportionately higher
than in women [2], perhaps because men are older when
they develop their osteoporotic fractures and have, therefore,
more comorbid conditions. Because men have not been the
center of attention in this disease, the data supporting the
use of teriparatide are not as secure as in postmenopausal
women, a point that is also true for data related to the use
of antiresorptive therapy in osteoporotic men. In this report,
we summarize the available data on the use of osteoanabolic
therapy in male osteoporosis.
2. Anabolic Activity of Parathyroid Hormone
Parathyroid hormone (PTH) has the interesting property of
harboring both catabolic and anabolic proclivities in bone.
The prototypical disease that illustrates best the catabolic
disposition of PTH is primary hyperparathyroidism. It is
of interest that the property to resorb bone in primary
hyperparathyroidism is seen most in the cortical skeleton
with cancellous bone being relatively spared [3]. In fact,
microarchitectural studies of cancellous bone in primary
hyperparathyroidism suggest that even under conditions
of chronic excessive exposure to PTH, microstructure is
maintained, if not enhanced [4]. This clue to the anabolic
potentialofPTHisrealizedbylow-dose,intermittentadmin-
istration of teriparatide or PTH(1-84). The mechanisms by
which PTH induces an anabolic eﬀect on bone are likely to
be multifactorial, including a number of pathways such as2 Journal of Osteoporosis
Wnt (via stimulating Wnt 10b [5], and inhibiting sclerostin
[6]), Runx2, and insulin-like growth factor (IGF-I). The
net eﬀect of low-dose, intermittent PTH exposure is an
initial recruitment of osteoblast progenitor cells and direct
stimulation of mature osteoblasts [7].
In both men and women, PTH increases bone mineral
density (BMD) in the lumbar spine, a site rich in cancellous
bone (Figure 1). Increases in the hip region are more modest
and PTH therapy reduces BMD at the distal 1/3 radius,
ac o r t i c a ls i t e .T h ee a r l ye ﬀect of PTH is an initial rapid
increase in bone formation markers subsequently followed
by an increase in bone resorption markers (Figure 2). These
changes in bone formation markers are accompanied by
histomorphometric observations that conﬁrm an eﬀect of
PTH to increase processes associated with bone formation
without any early evidence for bone resorption (Figure 3).
This eﬀect is reminiscent of bone metabolism in growing
children in whom bone modeling is dominant. Thereafter,
teriparatide leads to an increase in bone resorption giving
risetothemoretypicalcharacteristicsofbonemetabolism in
adults, namely, bone remodeling. Approximately 30% of the
overall eﬀect of PTH is thought to be due to the early eﬀect
on bone modeling with the majority being the subsequent
action of PTH to stimulate bone remodeling. The period of
time when PTH stimulates bone formation directly, before
bone remodeling is stimulated, is explained by the concept
of the “anabolic window” [8]( Figure 4). Even after bone
turnover is stimulated, there is more bone formation than
bone resorption ongoing, thus maintaining the anabolic
window at least for a ﬁnite period of time.
3. Indications for Teriparatide Use
Teriparatide (PTH(1-34)) was approved by the United
States Food and Drug Administration (FDA) in 2002 for
the treatment of osteoporosis in men and postmenopausal
women at high risk of fracture and in 2009 for the treatment
of glucocorticoid-induced osteoporosis in men and women
at high risk for fracture. Hodsman et al. [9]proposedcriteria
toestablishtheconditionof“highrisk,”includingpreexisting
osteoporotic fractures, very low bone density (T-score ≤
−3.5), and/or an unsatisfactory response to antiresorptive
therapy. An unsatisfactory response to antiresorptive ther-
apy, or drug failure, could be argued in the context of
an incident fracture during treatment or gastrointestinal or
other intolerance to bisphosphonates.
4. Teriparatide in Male Osteoporosis
Although both teriparatide and PTH(1-84) are available
widely for the treatment of postmenopausal osteoporosis,
only teriparatide has been studied and is available in men.
The results of clinical trials with teriparatide in men, while
more limited and less conclusive than those in women, show
nevertheless results that are similar to larger studies in post-
menopausal women. Kurland et al. [10] performed the ﬁrst
randomized trial evaluating the use of PTH(1-34) in men
with idiopathic osteoporosis. The double-blind, placebo-
controlled trial included 13 controls and 10 men treated with
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Figure 1: Changes in lumbar spine bone mineral density with
teriparatide 20µg daily. Although the ﬁgure does not show a head-
to-head comparison, the increase in bone mineral density in men
over the 11 months of the trial by Orwoll et al. tracks closely along
the trajectory in bone mineral density women over the same period
of time in the trial of Neer et al. (from Satterwhite et al. [26]).
teriparatide 400 IU daily (approximately equivalent to 25µg
daily) for 18 months. There was a 13.5% increase in BMD at
the lumbar spine in the PTH-treated group compared with
controls (P<0.001). Femoral neck BMD in the treatment
group increased, however, more slowly and to a lesser extent
(2.9% at 18 months; P<0.05), and there was no signiﬁcant
change in the 1/3 distal radius site. Markers of bone turnover
increased rapidly in the teriparatide-treated cohort, with
boneformationmarkersrisingandpeakingearlierthanbone
resorption markers.Thesedatademonstratethattheconcept
of a PTH-induced anabolic window is valid for men as well
as women.
Inalargerclinicaltrialthatwasalsorandomized,double-
blinded and placebo-controlled, Orwoll et al. [11] studied
437 men with idiopathic or hypogonadal osteoporosis. Men
were assigned to placebo (147 men), teriparatide 20µgd a i l y
(151 men), or teriparatide 40µg daily (139 men). The trial
was terminated prematurely, after only 11 months because of
the rat osteosarcoma toxicity results (see Section 6). Lumbar
spine and femoral neck BMD increased by 5.9% and 1.5%
respectively (P<0.05 in the 20µg group versus placebo).
There were even larger increases in BMD at the 40µgg r o u p ,
but adverse events were more frequently encountered.
Individuals in the study by Orwoll et al. were followed
for up to 30 months after teriparatide was discontinued as
part of a safety study [12]. Radiographs were available for
comparison between baseline and 18 months after treatment
discontinuation in 279 of the 437 men. The risk of new
vertebral fractures in men treated with teriparatide (20 and
40µg groups were combined) was reduced by 51% versus
placebo (P = 0.07). Absolute risk reduction was 6%, similar
to the fracture reduction data in women [13]. When onlyJournal of Osteoporosis 3
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Figure 2: Changes in bone turnover markers after teriparatide administration to men with osteoporosis. Bone formation markers increase
before bone resorption markers after men are exposed to teriparatide. Bone ALP, bone alkaline phosphatase; PICP, procollagen I carboxy-
terminal; NTX/CR, urinary N-telopeptide/creatinine ratio; fDPD/CR, free deoxypyridinoline/creatinine ratio; TPTD20, teriparatide 20µg;
TPTD40, teriparatide 40µg. From Orwoll et al. [11].
moderate or severe vertebral fractures were assessed, the
diﬀerencefromtheplacebogroupreachedsigniﬁcance(6.8%
versus1.1%;P<0.01).Inthe114menwhohadapreexisting
vertebral fracture at baseline, the absolute risk reduction for
new vertebral fractures was 13.1%. In the follow-up period,
other osteoporosis therapies were used, complicating the
analysis and raising the possibility that subsequent treatment
might have aﬀected the fracture outcome data. More men
in the placebo group received other treatment than those
who received teriparatide (36% versus 25%; P = 0.03),
suggestingthatthisconfoundingpointmightnotbeanissue.
However, it is possible, if not likely, that those receiving
further treatment after the clinical trial period had more
severe osteoporosis. The greater use of osteoporosis therapy
after the clinical trial was terminated was in the placebo
group and thus, does not negate this confounder.
Glucocorticoid-induced osteoporosis (GIO) is the most
common secondary cause of osteoporosis. Its major his-
tomorphometric and dynamic element is reduced bone
formation, a feature that may make GIO particularly well
suited to an osteoanabolic approach. Saag et al. [14]
compared alendronate and teriparatide in a head-to-head,
randomized, double-blind, double-dummy trial of 83 men
and 345 women with glucocorticoid-induced osteoporosis.
All subjects had received 5mg of daily prednisone, or the
equivalent, for at least 3 months. In addition, enrollment4 Journal of Osteoporosis
Teriparatide Control
Quadruple labels in teriparatide-treated and
control subjects
Figure 3: Early eﬀects of teriparatide to increase bone modeling.
Subjects were labeled before and 1 month after exposure to teri-
paratide. The control subjects did not receive treatment. The two
sets of labels in the teriparatide-treated subject clearly demonstrate
a marked increase in bone formation after teriparatide exposure.
From Lindsay et al. [27].
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Figure 4: The anabolic window. The ﬁgure demonstrates the
concept that bone formation is ﬁrst stimulated by teriparatide or
PTH(1-84) followed by an increase in bone resorption (adapted
from [8]).
criteria included baseline lumbar spine or total hip T-scores
≤− 2.0o r≤− 1.0 with at least 1 fragility fracture during
glucocorticoid treatment. An equal number of subjects
(n = 214) received either daily teriparatide 20µgo rd a i l y
alendronate 10mg. The change in lumbar spine BMD (the
primary end point) was greater in the teriparatide group,
as early as 6 months after therapy was started, and by 18
months, the teriparatide group (+7.2%) was signiﬁcantly
greater (P<0.001) than the alendronate group (+3.4%).
When the men were analyzed separately from the women,
the diﬀerences between teriparatide and alendronate were
virtually identical to the combined data for men and women
(7.3% versus 3.7%; P = 0.03) [15]. Total hip BMD in men
increased signiﬁcantly from baseline in the teriparatide
group only. Although this study was not powered to detect
ad i ﬀerence in fractures, they were captured as a reporting
item. Notably, there were signiﬁcantly fewer new vertebral
fractures in the teriparatide group than in the alendronate
group (0.6% versus 6.1%; P<0.01). In the men, there were
4 new vertebral fractures in the alendronate group and none
in the teriparatide group (P = 0.05).
This study was extended for an additional 18 months,
with ﬁndings that continued to show major diﬀerences
between those who were treated with teriparatide or alen-
dronate. After 36 months, increases in lumbar spine and
femoral neck BMD from baseline were signiﬁcantly (P<
0.001) greater in the teriparatide group than in the alen-
dronate group (11.0% versus 5.3% (lumbar spine); 6.3%
versus 3.4% (femoral neck)) [16]. The major diﬀerence in
fractureincidencewasalsomaintainedafter36monthswhen
the teriparatide and alendronate groups were compared
(1.7% versus 7.7%; P = 0.007).
5. Combination or SequentialTreatment with
TeriparatideandAntiresorptiveTherapy
5.1. Antiresorptive Therapy Prior to Teriparatide. Therapy
with teriparatide typically follows a course of bisphospho-
nate or other antiresorptive therapy. In Europe, virtually all
subjects who receive teriparatide or PTH(1-84) therapy have
been previously treated with a bisphosphonate. Sequential
therapy with an antiresorptive followed by teriparatide has
only been studied in women, with the results suggesting
that the potency of the antiresorptive drug to reduce bone
turnover tends to determine whether or not there will be a
delay in responsiveness to teriparatide. For example, bone
markers in prior alendronate-treated patients increase later
and peak at lower levels than in patients previously treated
with raloxifene [17]. In a head-to-head comparison between
risedronate and alendronate, the response to teriparatide
was more rapid and greater in subjects previously treated
with risedronate, but the results were not explained by the
smaller eﬀect of risedronate than alendronate to reduce
bone turnover markers. These observations, made only in
postmenopausal women, have not led to a general recom-
mendation to wait for a period of time after bisphosphonate
therapy before teriparatide is started. Eventually and rather
soon after teriparatide therapy is started, bone turnover
markers and BMD will begin to increase.
5.2. Combination Therapy. Finkelstein et al. [18]e v a l u a t e d
the simultaneous use of bisphosphonate and teriparatide
in 83 osteoporotic men who were randomized to receive
alendronate 10mg (28 men), teriparatide 40µg( 2 7m e n ) ,o r
both (28 men) on a daily basis. Alendronate was given for 30
months, with teriparatide started at month 6 and continued
for 24 months. The amount of daily teriparatide was twice
the FDA-approved 20µg dose. After 30 months, BMD at the
lumbar spine increased to a greater extent in men treated
with teriparatide alone than in the other groups (18.1%
teriparatide versus 14.8% combination, or versus 7.9%Journal of Osteoporosis 5
alendronate; P<0.001). Femoral neck BMD also increased
to a greater extent in the group treated with teriparatide
alone (9.7% teriparatide versus 6.2% combination, or versus
3.2% alendronate; P = 0.001). Increases in vertebral
trabecular BMD as determined by quantitative computed
tomography (QCT) were markedly higher with teriparatide
alone (48% teriparatide versus 17% combination, or versus
3% alendronate; P<0.001). Bone turnover markers in
the combination group were similar to those seen in the
group treated with alendronate alone, namely, a rapid
decrease in markers of both formation and resorption [19].
This lack of an eﬀect of teriparatide in combination with
alendronatetoincreaseboneturnovermarkersconﬁrmsdata
in women who were evaluated with a protocol that diﬀered
only slightly (shorter time period; PTH(1-84) instead of
teriparatide) [20]. Deal et al. [21] found that in women,
the combination of teriparatide with raloxifene, a less potent
antiresorptive agent, may enhance the bone-forming eﬀects
of teriparatide. In the study by Deal et al., bone formation
markers increased with combination therapy to an extent
similar to teriparatide alone while bone resorption markers
did not increase to the same extent as teriparatide alone,
suggesting that the anabolic window was greater with this
approach to combination therapy. More recently, Cosman
et al. [22] found that the combination of a single dose of
zoledronic acid with daily teriparatide increased BMD after
6 months at the spine and hip to a greater degree than either
drug alone. However, the major diﬀerences after 6 months
were much less apparent at the end of the 12-month study.
5.3. Antiresorptive Therapy Following Teriparatide. Kurland
etal.[10]weretheﬁrsttoshowinmenthatwhenteriparatide
is not followed by an antiresorptive agent, lumbar spine
and hip bone density falls precipitously. In those whose
teriparatide therapy is followed by alendronate, gains in
lumbar spine and hip BMD are maintained [23]. Although
not as clearly deﬁnitive, Kaufman et al. [12] also showed
that lumbar spine and hip BMD tended to decline in
men previously treated with teriparatide who received no
subsequent treatment for osteoporosis. These results are
similar to those observed in women [13]. Despite the
lack of fracture outcome data, the results of these studies
establish the importance of maintenance treatment with an
antiresorptive following the recommended 2-year course of
teriparatide therapy.
5.4. Teriparatide Retreatment. Subjects who completed the
30 month trial of Finkelstein et al. [18] comparing the
eﬀects of alendronate, teriparatide, or both on BMD and
bone turnover were monitored for 12 months after therapy
was discontinued and then randomized again to treatment
with alendronate, teriparatide, or both for an additional
12 months [24]. Only the data for the group receiving
teriparatide alone for 2 years, followed by 1 year of no
therapy, then 1 year of teriparatide retreatment (n = 21)
were presented. Not surprisingly, bone turnover markers
and BMD fell when teriparatide was stopped. Teriparatide
retreatment for 12 months resulted in an increase in lumbar
spine BMD of 5.2%, compared with 12.5% during the ﬁrst
12 months of treatment (P<0.001). Bone turnover markers
alsoincreasedmoreduringtheﬁrst12monthsofteriparatide
treatment as compared to the 12 month retreatment period.
The authors interpreted the data to reﬂect an attenuated
response to teriparatide retreatment. The possibility remains
that gains may have been greater if treatment had been
continued beyond the ﬁrst retreatment year.
6. Safety of PTH
Teriparatide is well tolerated in men and women. The FDA-
approved treatment regimen is 20µgd a i l yf o ru pt o2 4
months. Clinical trials have shown a very small risk of
hypercalcemia at the 20µgd o s e[ 11, 13]. In the postapproval
period, the risk of hypercalcemia appears to be even lower
than previously thought. Hypercalcemia is even less likely to
occur if calcium supplementation is reduced by 500mg/day
when teriparatide is initiated. Teriparatide does not appear
to signiﬁcantly increase urinary calcium excretion [11, 12].
In the animal toxicity studies, male and female rats
treated with teriparatide or PTH(1-84) at doses that were 3–
60-times the equivalent dose to human subjects for 75 years
of human equivalent time develop osteosarcoma [25]. This
rat toxicity has not been seen in monkeys. With almost 9
years of clinical experience, the number of reported cases
of osteosarcoma in patients is even less than expectations
based upon epidemiological data of osteosarcoma in human
subjects not treated with PTH. With no more than 3 cases
reportedamongapproximately1.5millionsubjectswhohave
received teriparatide or PTH(1-84) worldwide, this toxicity
does not appear to be a human one.
There are contraindications to the use of teriparatide,
such as primary hyperparathyroidism. It should not be
used in children with open epiphyses, in subjects at risk
for osteosarcoma (Paget’s disease of bone; previous external
ionizing skeletal irradiation), or in subjects with a previous
history of osteosarcoma. An unexplained elevation in the
alkaline phosphatase is also a relative contraindication to
teriparatide use.
7. Conclusions
Teriparatide, the only available osteoanabolic agent for men,
is indicated for the treatment of osteoporosis when fracture
risk is high. It is also indicated for the treatment of men
with glucocorticoid-induced osteoporosis. The data for men
in terms of increases in bone density and changes in
bone turnover markers track virtually identically with the
more extensive data that are available for postmenopausal
women. Reduction in fracture incidence, although not
conclusive, also appear to mirror the more extensive and
conclusive data in women. Teriparatide is well tolerated for
the recommended 2-year treatment period, and it should
be followed by an antiresorptive drug to maintain increases
in bone density. Combination therapy with antiresorptives
has not been shown to be superior to monotherapy with
teriparatide alone. Ongoing research, however, may oﬀer6 Journal of Osteoporosis
new insights into eﬀective approaches to combination or
sequential osteoanabolic and antiresorptive therapy.
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